Form 4: Cardlytics Director Klinck Jr. Reports Stock Transactions
SEC Form 4 Filing
Director John L. Klinck Jr. reports the vesting and conversion of restricted stock units into Cardlytics common stock.
Summary
- On May 23, 2025, John L. Klinck Jr., a director of Cardlytics, Inc., reported a transaction involving restricted stock units (RSUs).
- 11,000 RSUs vested and were converted into 11,000 shares of Cardlytics common stock.
- The price per share for the conversion was $0.
- Following the transaction, Klinck Jr. directly owns 78,593 shares of Cardlytics common stock.
- The RSUs vested in full on the one-year anniversary of the date of grant.
Sentiment
Score: 5
Explanation: This is a neutral reporting of a routine transaction. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the vesting of previously granted compensation.
Stakeholder Impact
- The transaction has a minor dilutive effect on existing shareholders due to the issuance of new shares.
Key Dates
| Date | Description |
|---|---|
| 05/23/2025 | Date of transaction: vesting and conversion of restricted stock units. |
Keywords
Cardlytics, Director, Stock, RSU, Klinck, CDLX, Form 4, Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.